Physiology and Histology Effect of Orlistat Drug in Pancreas Tissue of Male Albino Rat

Abstract

Introduction: Orlistat is the only medication for long-term control of obesity that the FDA has approved. By inhibiting Pancreatic lipase, it decreases the absorption of dietary fat. Aim of the work: The purpose of the current study is to provide light on potential orlistat side effects on healthy pancreatic tissue and how these changes may affect the physiology of the lipase enzyme. Materials & Methods: We study of 32 male albino rats obese with mean age 12 weeks. The animal divide to four Groups and all group included of these 8 animals. The first group is control, second group (120 mg/kg/day), third group (180 mg/kg/day) and forth group (240 mg/kg/day) for 12 weeks of treatment. Results: the results showed lipase pancreatic in group 4(240 mg /kg/day) (85.142 ± 2.761) and group 3 (180 mg/kg/day) (126.047± 0.671) vs control group (159.812±1.606) the result showed decrease in level of lipase pancreatic compared to other groups. Orlistat caused variable degrees of pancreatic tissue degeneration, dilatation of pancreatic ducts with retained secretion, and congestion. Inflammatory cells infiltration observed in pancreatic acini and vascular congestion within islets of Langerhans with high dose (180,240 mg / kg/ day). Conclusion: Orlistat may induce pancreatic duct with retained secretion, vascular congestion production. of pancreas Orlistat should be prescribed as a treatment for obesity keeping in mind that these effects are dose dependent.